---
title: "Newland Pharmaceutical Co., Ltd. (301277.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/301277.SZ.md"
symbol: "301277.SZ"
name: "Newland Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T11:56:49.861Z"
locales:
  - [en](https://longbridge.com/en/quote/301277.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301277.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301277.SZ.md)
---

# Newland Pharmaceutical Co., Ltd. (301277.SZ)

## Company Overview

Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, lidocaine, gatifloxacin, febuxostat, esomeprazole sodium, and esomeprazole magnesium.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.newlandpharma.com](https://www.newlandpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.51)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 144 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -13.41% |  |
| Net Profit YoY | -42.18% |  |
| P/B Ratio | 2.70 |  |
| Dividend Ratio | 1.83% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4289111648.77 |  |
| Revenue | 660710105.07 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.32% | C |
| Profit Margin | 15.28% | A |
| Gross Margin | 31.61% | C |
| Revenue YoY | -13.41% | E |
| Net Profit YoY | -42.18% | D |
| Total Assets YoY | -1.32% | D |
| Net Assets YoY | -0.87% | D |
| Cash Flow Margin | 60.45% | C |
| OCF YoY | -13.41% | E |
| Turnover | 0.36 | C |
| Gearing Ratio | 12.96% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Newland Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-13.41%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-42.18%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.70",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.83%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4289111648.77",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "660710105.07",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.32%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "15.28%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "31.61%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-13.41%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-42.18%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.32%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.87%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "60.45%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-13.41%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.36",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "12.96%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 42.48 | 92/215 | 40.88 | 38.77 | 35.81 |
| PB | 2.70 | 125/215 | 3.63 | 3.33 | 3.07 |
| PS (TTM) | 6.49 | 148/215 | 7.83 | 7.39 | 6.99 |
| Dividend Yield | 1.83% | 71/215 | 2.33% | 2.18% | 1.92% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/301277.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/301277.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/301277.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/301277.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**